Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Jamjoom Pharma

    • Home
    • Jamjoom Pharma
Company Deals

Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA

Fineline Cube Sep 15, 2025

Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced on September 15, 2025, that it has entered...

Company Deals

Zhaoke Ophthalmology Partners with Jamjoom Pharma for Cyclosporine Eye Gel Distribution in Middle East

Fineline Cube Jul 1, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi...

Recent updates

  • Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion
  • Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030
  • Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative
  • Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows
  • Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion

Company Deals

Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030

Company Deals Hospital

Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative

Company

Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.